Leptin Gene Epigenetic Adaptation to Impaired Glucose Metabolism during Pregnancy

Luigi Bouchard\textsuperscript{1,2} Ph.D. MBA, Stéphanie Thibault\textsuperscript{1,2} B.Sc., Simon-Pierre Guay\textsuperscript{1,2} B.Sc., Marta Santure\textsuperscript{1,2} Ph.D., Alexandre Monpetit\textsuperscript{3} Ph.D., Julie St-Pierre\textsuperscript{4} MD Ph.D., Patrice Perron\textsuperscript{2,5} MD M.Sc. and Diane Brisson\textsuperscript{1,2} Ph.D. CCRP.

1. Department of Medicine, Université de Montréal, Montréal, QC, Canada; 2. ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital, Saguenay, QC, Canada; 3. McGill University and Génome Québec Innovation Centre, Montréal, Canada; 4. Faculty of Pharmacy, Université Laval, Québec, QC, Canada and 5. Department of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada.

Running title: Leptin DNA methylation in gestational diabetes

Address correspondence to:
Luigi Bouchard, Ph.D. MBA
E-mail: luigi.bouchard@recherche-caurc.org

Submitted 31 May 2010 and accepted 4 August 2010.

Additional information for this article can be found in an online appendix at http://care.diabetesjournals.org

This is an uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association, publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes Care in print and online at http://care.diabetesjournals.org.
**Objective:** To verify whether the leptin gene epigenetic (DNA methylation) profile is altered in the offspring of mothers with gestational impaired glucose tolerance (IGT).

**Research Design and Methods:** Placenta tissues, maternal and cord blood samples were obtained from 48 women at term including 23 subjects with gestational IGT. Leptin DNA methylation, gene expression levels and circulating concentration were measured using the Sequenom EpiTYPER system, quantitative real-time RT-PCR and ELISA respectively. IGT was assessed following a 75g-oral glucose tolerance test (OGTT) at 24-28 weeks’ gestation.

**Results:** We have shown that placenta leptin gene DNA methylation levels were correlated with glucose levels (2-h post-OGTT) in women with IGT (fetal side: rho = -0.44, p ≤ 0.05 and maternal side: rho = 0.53, p ≤ 0.01) and with decreased leptin gene expression (n = 48; rho ≥ -0.30, p ≤ 0.05) in the whole cohort. Placenta leptin mRNA levels accounted for 16% of the variance of maternal circulating leptin concentration (p < 0.05).

**Conclusion:** IGT during pregnancy was associated with leptin gene DNA methylation adaptations with potential functional impacts. These epigenetic changes provide novel mechanisms that could contribute to explain the detrimental health effects associated with fetal programming such as long-term increased risk of developing obesity and type 2 diabetes.

The fetal programming or Barker’s hypothesis states that increased risk of developing obesity and diabetes in adulthood originate from the fetal exposure to detrimental environments such as impaired glucose tolerance (IGT) and gestational diabetes mellitus (GDM) (1). However, the molecular mechanisms connecting pre- and perinatal exposure to high glucose and insulin levels with an increased long-term risk for health have not yet been identified. Our hypothesis is that the reprogramming of the newborn’s energy metabolism through epigenetic changes or adaptation in response to detrimental fetal environment contributes to explain the long-term interindividual variability in obesity and diabetes risk. Therefore, comparing epigenetic differences between placenta tissues exposed or not to IGT could help better define the role of epigenetics in fetal programming.

Epigenetics denotes molecular mechanisms independent of the DNA sequence that refer to the heritable, but also reversible, regulation of gene transcription (2). Epigenetic marks are subjected to reprogramming in response to both stochastic and environmental stimuli such as changes in diet and in utero environment (3). Indeed, epigenetic marks can be mitotically-stable and enduring, producing long-term changes to gene expression (4) and phenotypic variability. The DNA methylation that takes place at position 5' of the cytosine (C^{met}) pyrimidine ring is the most stable and best understood epigenetic marks (5).

Leptin is a well-recognized obesity and diabetes candidate gene for which proximal promoter demethylation has been shown to induce its gene transcription in mature adipocytes (6). This adipocytokine is involved in the energy metabolism and insulin sensitivity control and is expressed and secreted by the placenta during pregnancy (7). It follows that leptin expression and plasma levels are increased in obesity and diabetes, as well as during pregnancy (8; 9). Accordingly, leptin is a strong candidate gene for DNA methylation studies in order to verify whether epigenetic mechanisms are affected by
glucose metabolism dysregulation during pregnancy.

The goals of this study were thus to assess whether leptin promoter DNA methylation shows adaptation (or variability) to IGT during pregnancy and to which extent these changes have functional consequences on leptin gene expression and circulating levels.

MATERIAL AND METHODS

Subjects. Forty-eight women with a singleton pregnancy were recruited in the Saguenay area from a founder population of French-Canadian origin (self-reported and confirmed by the last name and first language). Women over 40 years old, with pre-gestational diabetes or other disorders known to affect glucose metabolism as well as those with a positive history of alcohol and/or drug abuse during the current pregnancy were excluded. The Chicoutimi Hospital Ethics Committee approved the project. All women provided a written informed consent before their inclusion in the study in accordance with the Declaration of Helsinki.

Anthropometric variables (BMI, waist and hip girth) and blood pressure were measured using standardized procedures (10). Glucose was evaluated using a Beckman analyzer (model CX7; Fullerton, CA), and insulin measurements were performed using a radioimmunoassay method (Advia Centaur, Simmens). Serum leptin levels were measured using ELISA assay as recommended by the manufacturer (B-bridge International, USA).

IGT was defined as a 2-hour glucose ≥7.8 mmol/L following a 75-g oral glucose tolerance test (OGTT) performed at 24-28 weeks’ gestation. Women with IGT were controlled with diet only (n=14) or with diet and insulin treatment (n=7). Two IGT mothers did not receive any treatment.

Placenta tissue sampling. Placenta tissues were sampled in the minutes following delivery (on average, less than 15 minutes) and kept in RNALater (Qiagen, Valencia, CA) at -80ºC until nucleic acid extraction. Tissue biopsies were taken from the fetal and the maternal sides. The former consisted of the inter villous tissues and chorionic villi, and the latter consisted mainly of fetal villous tissue but also contained tissue of maternal origin in the decidua basalis (basal plate). Analyses were performed on both sides independently.

Leptin DNA methylation and mRNA level measurements. DNA and RNA were purified using the All Prep DNA/RNA/Protein mini Kit (Qiagen). RNA quality was assessed with the Agilent 2100 bioanalyzer RNA Nano Chips (Agilent Technology). On average, the RNA showed good integrity (mean RNA Integrity Number = 7.63).

The gold standard Sequenom EpiTYPER® system was used to determine base-specific cytosine methylation levels (11). This assay combines sodium bisulfite DNA conversion chemistry (EpiTect Bisulfite Kits, Qiagen); PCR amplification (Pyromark PCR kit; Qiagen) of the target sequence; and base specific cleavage. Sodium bisulfite preferentially deaminates unmethylated cytosine residues to thymines, whereas methylcytosines remain unmodified. Consequently, the base-specific cleavage pattern will be affected by the presence of methylated cytosine within the original DNA sequence. The cleavage products were analyzed by MALDI-TOF mass spectrometry in which the size ratio of the cleaved products provides quantitative methylation estimates for each CpG site within the target sequence (11). The PCR primers for leptin gene CpG island locus amplification were: 5’-ACCACCCCCAAATTTT-3’ and 5’-AGATTAGTAGAGAAGGAGGAAGGA-3’. One out of the 96 DNA samples (from the fetal side, IGT group) did not amplify and was therefore not analyzed.

Complementary DNA (cDNA) was generated from total RNA using a random primer hexamer provided with the High
Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA). Equal amounts of cDNA were run in duplicate and amplified in a 20 µl reaction containing 10 µL of 2X Universal PCR Master Mix (Applied Biosystems). Primers and Taqman probes were obtained from Applied Biosystems (Leptin: Hs00174877_m1; Applied Biosystems). Each sample was calibrated to the YWHAZ housekeeping gene (endogenous control; YWHAZ: Hs00237047_m1) (12; 13). Relative quantification estimations were performed using an Applied Biosystems 7500 Real Time PCR System as recommended by the manufacturer (Applied Biosystems).

**Statistical analyses.** Women with normal glucose tolerance (NGT) and IGT were matched for maternal age and first trimester BMI. Student t-tests were applied to determine whether mean group differences were statistically significant (p < 0.05).

Fetal and maternal sides mean locus DNA methylation for each sample was calculated among the cytosines with mean DNA methylation levels greater than 10% across samples. Leptin/YWHAZ c ratio (1/x) values were used for correlation analyses.

First, the correlation between the dependent variables (leptin DNA methylation, mRNA and circulating levels) and possible confounders (age, BMI, weight changes, insulin levels) was tested. Leptin DNA methylation, mRNA and cord blood leptin levels were not correlated with any of these possible confounders. However, third trimester serum leptin levels were correlated with first trimester BMI (rho = 0.39, p = 0.01). On the other hand, leptin cord blood levels were found to be correlated with birth weight (rho = 0.47, p = 0.01). Accordingly, first trimester BMI and birth weight were included in statistical models testing association with third trimester serum and cord blood leptin levels respectively. Secondly, statistical interaction between 2-h post-OGTT glucose levels and IGT status has been tested using the general linear model (GLM). Significant interactions were found for leptin DNA methylation (fetal side placenta: p_{inter} = 0.035; and maternal side placenta: p_{inter} = 0.029) but not for leptin mRNA and circulating levels. Accordingly, correlation analyses for leptin DNA methylation were conducted in both groups separately. Correlations were tested using (partial) Spearman rank correlation coefficients (rho). P-values were two-sided. Statistical analyses were performed using the SAS software, version 9.1.3.

**RESULTS**

Table 1 shows women’s and newborn’s physical and metabolic characteristics. On average, IGT women gained less weight during pregnancy and had decreased third trimester serum leptin levels as compared to the NGT group. Cord blood leptin levels were decreased by almost 35% in the IGT group. No other significant difference between the two groups was found. Nevertheless, third trimester serum and cord blood leptin levels were negatively correlated with 2-h post-OGTT glucose levels (rho = -0.57, p = 0.0002 and rho = -0.33, p = 0.043 respectively). Therefore, placental leptin gene DNA methylation and expression levels have been assessed in both the fetal and the maternal sides of the placenta to determine whether they were also dysregulated according to 2-h post-OGTT glucose levels and IGT status.

DNA methylation analyses targeted the region of the leptin gene promoter that has already been shown to be subjected to demethylation associated with leptin gene transcription activation during preadipocyte maturation into adipocyte (6). In fact, our analyses covered 31 out of 42 cytosines located within the leptin gene proximal promoter CpG island (Figure 1 and Supplementary Table 1 in the online appendix available at [http://caqre.diabetesjournals.org](http://caqre.diabetesjournals.org)). Mean DNA methylation levels greater than
10% were observed for 20 and 26 CpG sites in the fetal and the maternal placenta sides respectively (Figure 2). Within the same placenta side, CpG site pairwise DNA methylation correlation was moderate to high (rho ≥ 0.50, p ≤ 0.0001). However, most of the correlation between fetal side and maternal side CpG methylation did not reach the level of statistical significance (rho ≤ 0.30, p > 0.05) (data not shown).

No significant difference was found between groups for mean leptin gene DNA methylation levels (Table 1). However, mean DNA methylation was found to be significantly correlated with glucose levels (2-h post-OGTT) in the IGT group (Figure 3 A and B). Interestingly, the correlation coefficient showed opposite trends between fetal and maternal placenta tissues (Figure 3 A and B). Of note, most CpG sites provided very similar results when analyzed separately (data not shown). No correlation between leptin DNA methylation and glucose levels 2-h post-OGTT was observed in the NGT group (n = 25) (data not shown).

The functional impacts of the observed leptin gene DNA methylation variability on leptin gene transcription and circulating levels were then assessed. On the one hand, we found that the leptin gene DNA methylation was associated with decreased leptin gene mRNA levels in both types of placenta tissues (Figure 3 C and D). On the other hand, although increased leptin gene expression levels in both the fetal and the maternal sides were correlated with third trimester circulating leptin levels (corrected for first trimester BMI) (Figure 3 E and F), the correlations between DNA methylation and circulating (third trimester serum and cord blood) concentrations were not found to be significant.

**DISCUSSION**

To the best of our knowledge, this is the first study in humans focusing on the effect of gestational impaired glucose tolerance (gestational diabetes) on the newborn epigenetic profile. The most important finding is to have shown that placenta DNA methylation is correlated with mother’s glycemia during pregnancy. Interestingly, the leptin DNA methylation showed adaptation only within the group above the IGT diagnostic criteria threshold (2-h post-OGTT glycemia > 7.8 mmol/L) suggesting that the leptin gene epigenetic profile will be affected by plasma glucose levels only above a critical threshold.

Although the fetal programming hypothesis is now well recognized, only a few studies have provided direct evidence that may support this concept. Of these, Tobi et al. have shown that DNA methylation at several genome loci harboring genes implicated in growth, development and energy metabolism (including the leptin gene) was dysregulated in human peripheral blood mononuclear cells obtained from adult subjects who had experienced prenatal exposure to famine decades before (14). We have observed that the correlations between 2-h post-OGTT glucose and placenta DNA methylation performed at the end of second trimester suggest that IGT-related DNA methylation adaptations are long lasting. Although, DNA methylation adaptations may have arisen during critical windows of fetal development (first trimester) (15), we cannot rule out that the placenta DNA methylation adaptation may also be related to the mother’s hyperglycemia at the end of gestation. Nevertheless, these results suggest that dysregulation of the DNA methylation profile may potentially have long-term consequences and suggest that the IGT-related DNA methylation changes we have observed have the potential to account for a long term and possibly transgenerational (16; 17) risk to develop obesity and type 2 diabetes associated with fetal programming. Accordingly, if GDM could be detected.
earlier and treated rapidly, IGT would likely be prevented along with epigenetic changes. This finding reinforces the need to identify early GDM markers.

Interestingly, the correlations between 2-h post-OGTT glucose levels and leptin DNA methylation showed opposite trends in fetal and maternal sides suggesting that both placenta sides are differently affected by the mother’s IGT. Although the biological reasons will not be simple to explain, we can hypothesize that the materno-fetal glucose transport dysregulation associated with GDM (18) contributes to expose both sides of the placenta to different glucose and insulin concentrations. In accordance and contrary to what we have observed in maternal circulation, cord blood glucose and insulin levels failed to be correlated with each other, suggesting that glucose metabolism is fairly different on both sides of the placenta and may thus have a distinctive influence on the epigenetic profile. Furthermore, although the 2-h post OGTT glycemia explains between 19% and 28% of the DNA methylation variability at the leptin gene locus, a significant portion of the variability remains to be explained by other factors. Identifying those factors will be the focus of further studies and could possibly explain the DNA methylation differences between both sides of the placenta.

We have also shown that epigenetic variability at the leptin gene locus has functional consequences. However, although placental leptin gene expression levels have been associated with its circulating concentration, leptin gene DNA methylation itself has not been associated with its plasma levels. This raises the question about the influence of the placenta on leptin circulating levels. Although this influence is not obvious to assess, our results suggest that placenta leptin gene expression could account for up to 16% of the variance of maternal leptin circulating levels. Nevertheless, it is likely that the impact of placenta leptin DNA methylation variability on leptin circulating levels could have been missed due to the masking effect of other factors such as the adipose tissue leptin production. In all, the placenta contribution to leptin circulating levels is small but significant, and the relationship between leptin DNA methylation and circulating levels does not seem to be as straightforward as first thought. Nevertheless, the placenta leptin levels could have been affected by its DNA methylation variability but the leptin concentration could not be measured at tissue level in this study. Additional studies are therefore needed to explore this possibility.

It is well accepted that pregnancy is associated with an increased circulating leptin concentration (8), although it is still unclear whether plasma leptin concentration shows differences according to GDM status. A number of studies have been published reporting either increased, decreased or unchanged concentrations in GDM (19-22). Discrepancies between studies can be explained by GDM treatment (diet and exercise vs. insulin) as well as mother’s and newborn’s adiposity and weight gain differences between studies. Nevertheless, our results are in accordance with three studies reporting hypoleptinemia in similar cohorts of women with mild GDM (23; 24) and newborns of GDM mothers without insulin treatment (25) suggesting that leptin has beneficial effects on the mother’s glucose disposal and insulin sensitivity. This could also have short- and long-term consequences on mothers’ and newborns’ health.

One limitation of the current study is the lack of significant differences in placenta leptin DNA methylation and mRNA levels between NGT and IGT groups. Although 48 samples (total 96) can be considered a large sample size for DNA methylation and transcriptomic analyses with this very high phenotyping quality, it is possible that the
study was short of statistical power to find significant group differences. Also, we chose to study women with intermediate glucose intolerance instead of women with GDM. Therefore, we hypothesize that our results should at least remain unchanged with the more stringent GDM diagnosis criteria and may be even more significant. Unfortunately, we cannot verify this last hypothesis with our data since most of the women with glucose perturbations in our study sample had only a moderate glucose increase following the second trimester 75g-OGTT. None of them fulfilled the ADA GDM criteria. Nevertheless, the most important was clearly to have found significant correlations between leptin DNA methylation and 2-h post-OGTT glucose concentration, a recognized indicator of glucose metabolism status during pregnancy.

In summary, our results give a better understanding of the molecular mechanisms involved in fetal programming associated with pregnancy-related IGT. Since DNA methylation can be mitotically stable, leptin gene DNA methylation adaptations to IGT and the parallel transcriptional response that we have observed could have profound short- and long-term phenotypic effects. These effects could therefore contribute to explain why newborns exposed to a detrimental fetal environment (such as GDM) have an increased risk to develop obesity and type 2 diabetes later in life. Although it is largely speculative, we can hypothesize that increasing maternal glycemia leads to fetal leptin gene DNA demethylation, which leads to higher mRNA levels and subsequently higher leptin levels, possibly promoting leptin resistance and obesity development. Overall, these data provide supportive evidence for potential unfavorable molecular adaptations to the fetal environment. They also concur to support the idea that other genes could contribute to clarify the concept of molecular fetal programming.

**Authors Contributions.** L.B. has conceived the study design, performed the data analysis/interpretation and written the manuscript. S.T., S-P. G. and A.M. performed the data collection and revised the manuscript. M.S. participated to study design conception, P.P. and J. S-P. participated to study design conception and revised the manuscript, and DB participated to study design conception, participated to the data analysis/interpretation and revised the manuscript.

**ACKNOWLEDGMENTS** We warmly acknowledge the contribution of Sébastien Claveau (M.Sc.), Nadia Mior and Chantale Aubut (Inf.) for their dedicated work in this study. We also express our gratitude to Robert Sladek (MD, Ph.D.), McGill University, and Céline Bélanger, Chicoutimi Hospital, for their thoughtful revision of the manuscript. This project was supported by ECOGENE-21 (PI: Dr Daniel Gaudet (MD, Ph.D.) Montreal University), the Canadian Institutes of Health Research (CIHR team in community genetics (grant #CTP-82941), Fonds de la Recherche en Santé du Québec (FRSQ) and Diabète Québec. Simon-Pierre Guay is supported by a CIHR/Frederick Banting and Charles Best Canada Graduate Scholarship - Master's Awards and by the FRSQ.

**REFERENCES**
21. Simmons D, Breier BH: Fetal overnutrition in polynesian pregnancies and in gestational diabetes may lead to dysregulation of the adipoinsular axis in offspring. *Diabetes Care* 25:1539-1544, 2002


### Table 1. Women's and newborns' characteristics

<table>
<thead>
<tr>
<th></th>
<th>NGT Mean ±SD</th>
<th>IGT Mean ±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number</strong></td>
<td>25</td>
<td>23</td>
</tr>
<tr>
<td>Mother's age (years)</td>
<td>28.1 ±0.7</td>
<td>29.0 ±0.7</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; T body mass index (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>24.3 ±0.7</td>
<td>25.2 ±0.7</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; T fasting glycemia (mmol/L)</td>
<td>4.36 ±0.08</td>
<td>4.31 ±0.08</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; T fasting insulin (mU/L)</td>
<td>5.56 ±0.72</td>
<td>6.48 ±0.74</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; T fasting serum leptin levels (ng/mL)†</td>
<td>28.9 ±3.3</td>
<td>25.8 ±3.6</td>
</tr>
<tr>
<td>Weight gain between 1&lt;sup&gt;st&lt;/sup&gt; and 3&lt;sup&gt;rd&lt;/sup&gt; T (kg)</td>
<td>13.5 ±2.68</td>
<td>8.7 ±3.63*</td>
</tr>
<tr>
<td>3&lt;sup&gt;rd&lt;/sup&gt; T fasting serum leptin levels (ng/mL)§</td>
<td>44.1 ±4.72</td>
<td>25.7 ±5.1*</td>
</tr>
<tr>
<td>Maternal side placenta mean leptin DNA methylation levels (%)</td>
<td>28.1 ±1.4</td>
<td>29.4 ±1.4</td>
</tr>
<tr>
<td>Maternal side placenta leptin mRNA levels (AU)</td>
<td>1.00 ±0.02</td>
<td>1.01 ±0.02</td>
</tr>
<tr>
<td>Birth weight (kg)</td>
<td>3.35 ±0.10</td>
<td>3.27 ±0.10</td>
</tr>
<tr>
<td>Cord blood leptin levels (ng/mL)§</td>
<td>11.1 ±1.2</td>
<td>7.2 ±1.3*</td>
</tr>
<tr>
<td>Fetal side placenta mean leptin DNA methylation levels (%)</td>
<td>28.5 ±1.1</td>
<td>28.8 ±1.2</td>
</tr>
<tr>
<td>Fetal side placenta leptin mRNA levels (AU)</td>
<td>1.11 ±0.02</td>
<td>1.10 ±0.02</td>
</tr>
</tbody>
</table>

IGT was defined as a 2-hour glucose ≥7.8 mmol/L following a 75-g-oral glucose tolerance test (OGTT) performed at 24-28 weeks’ gestation. Unpaired *t*-test. * p<0.0001. 1<sup>st</sup> T = first trimester of gestation (between weeks 11-14); 2<sup>nd</sup> T = second trimester of gestation (between weeks 24 and 28); 3<sup>rd</sup> T = third trimester of gestation (between weeks 36 and 37); AU = arbitrary unit; NGT = normal glucose tolerance; and IGT = impaired glucose tolerance. † n=35 (NGT = 19 and IGT = 16); § n=43 (NGT = 23 and NGT = 20); and ¥ n=39 (NGT = 21 and IGT = 18).
Figure legends

Figure 1. Leptin gene CpG island proximal promoter region.
The forward CpG island sequence is shown in italic and delimited by hyphens. The leptin exon 1 sequence is bold typed. Arrows indicate both PCR primer sequences. Underlined cytosines have already been associated with demethylation and leptin gene transcription activation (6). The sequence has been numbered relative to the 1st leptin gene codon (exon 2; Ensembl release 56 (sept. 2009)). The CpG sites have been numbered relative to the 3’ of the amplicon. The CpG #31 corresponds to -204 position in Melzner et al. (6).

Figure 2. DNA methylation levels for each CpG site and sample analyzed. * Cytosines that contributed to the summary statistic.

Figure 3. Spearman correlation between A) and B) leptin DNA methylation and 2-hour post-OGTT glucose levels, within the IGT group; C) and D) leptin DNA methylation and mRNA levels; and E) and F) leptin mRNA levels and circulating concentrations measured at the end of the third trimester (between weeks 36 and 37) of pregnancy.

Note: Impaired glucose tolerance (IGT) was defined as a 2-hour glucose ≥7.8 mmol/L following a 75g-oral glucose tolerance test performed between 24-28 weeks’ of gestation; AU = arbitrary unit; †Leptin DNA methylation n=47 (NGT = 25 and IGT = 22); * adjusted for first trimester BMI; and †n=43 (IGT (-) = 23 and IGT (+) = 20).

Figure 1

```
...ATGCCCCCAGCCCCCTCCTCGGAGAGCAGCAGCCACCCCCGC
CCGCAAGGAGCAGCCCGCGAGCTGAAAGCTCCTCTACCACAGC
GATTCTCGCTCTCCTACTAGCGACACCCGCCCACACATACAG
CAAGAGCTCGGCGTCGGGTCCCTGGACGGCGCGGCTTCCCTCGA
GGCCGGGAGGGGCAGGCAGCTGCGCCGCCGGAGCAGCGCCG
GGCAGGTCGCTACCCGAGCGGGCGGGCGGGAGCTGCCGAGA
ATGCGCCGCGCTGCGGGCAGATGGCAGTGACATCGGGCC
GCTATAAGWGCGGGCCAGCAGCAGGGCCCAGTACCCGAGAG
CGCCARCGGTGCAAGTGGGGGCCCTCTCCTCTCCTCTCCCT
CTCTGCTGCTTCCCCCCGAGCCGCACAGGGGCCGCACAACTCT
GGATCCCCGGAATCGAGTCAGGGGGGATCGGCGGAGTGGC
TAGTTCAGGACTATAGGACTTTGACCAGAG...
```
### Figure 2

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Genes</th>
<th>Cpg 1-2 and 3*</th>
<th>Cpg 4-5 and 6*</th>
<th>Cpg 7*</th>
<th>Cpg 8 and 10*</th>
<th>Cpg 11*</th>
<th>Cpg 12</th>
<th>Cpg 13 and 14*</th>
<th>Cpg 15</th>
<th>Cpg 16 and 17*</th>
<th>Cpg 18</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>7</td>
<td>Male</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>8</td>
<td>Female</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>9</td>
<td>Male</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>10</td>
<td>Female</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>11</td>
<td>Male</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>12</td>
<td>Female</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
</tbody>
</table>

**Note:** Cpg bands are described for gestational diabetes.
Figure 3

- **A** Fetal side: $\rho = -0.44$, $p = 0.039$
- **B** Maternal side: $\rho = 0.53$, $p = 0.009$
- **C** $\rho = -0.30$, $p = 0.043$
- **D** $\rho = -0.47$, $p = 0.0009$
- **E** $\rho = 0.40^{* *}$, $p = 0.013$
- **F** $\rho = 0.38^{* *}$, $p = 0.020$